Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B2 | P80365 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | STS | P08842 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 2/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2080856 | 1.00 | HSD11B2 (0.42) | HSD11B2KDM4EPKMSPHK1BRD4 | |
| SCHEMBL2078387 | 1.00 | HSD11B2 (0.42) | HSD11B2KDM4EPKMSPHK1BRD4 | |
| SCHEMBL2082316 | 0.87 | BRD4 (0.43) | HSD11B2PKMSPHK1BRD4STS | |
| SCHEMBL2082319 | 0.87 | BRD4 (0.43) | HSD11B2PKMSPHK1BRD4STS | |
| SCHEMBL2080224 | 0.85 | BRD4 (0.42) | HSD11B2KDM4EPKMSPHK1BRD4 | |
| SCHEMBL2080227 | 0.85 | BRD4 (0.42) | HSD11B2KDM4EPKMSPHK1BRD4 | |
| SCHEMBL3614064 | 0.84 | KEAP1 (0.41) | HSD11B2KDM4EPKMSPHK1BRD4 | |
| SCHEMBL3614066 | 0.84 | KEAP1 (0.41) | HSD11B2KDM4EPKMSPHK1BRD4 | |
| SCHEMBL13110173 | 0.84 | KEAP1 (0.41) | HSD11B2KDM4EPKMSPHK1BRD4 | |
| SCHEMBL16087487 | 0.83 | HSD11B2 (0.39) | HSD11B2KDM4EPKMSPHK1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121641-B1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | HOFFMANN LA ROCHE (CH) | 2014-09-24 | — | — | EP | disclosed |
| EP-2121641-B1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | HOFFMANN LA ROCHE (CH) | 2014-09-24 | — | — | EP | disclosed |
| US-7902238-B2 | 2-aminooxazolines as TAAR1 ligands | HOFFMANN-LA ROCHE INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902238-B2 | 2-aminooxazolines as TAAR1 ligands | HOFFMANN-LA ROCHE INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902238-B2 | 2-aminooxazolines as TAAR1 ligands | HOFFMANN-LA ROCHE INC. (US) | 2011-03-08 | — | — | US | disclosed |
| EP-2121641-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | F. Hoffmann-Roche AG (CH) | 2009-11-25 | — | — | EP | disclosed |
| US-20090105307-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-23 | — | — | US | disclosed |
| US-20090105307-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-23 | — | — | US | disclosed |
| US-20090105307-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-23 | — | — | US | disclosed |
| WO-2008098857-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105307-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | TAAR1, TAAR5, NPSR1 | HSD11B2 1234/4885KDM4E 4041/4885PKM 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.